Overview

Evaluation of Oral PF614 Relative to OxyContin

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B). Both parts of the study will be conducted in healthy adult subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Ensysce Biosciences

Collaborator:

PRA Health Sciences

Treatments:

Naltrexone
Oxycodone